ASOPRSFall Scientific SymposiumSyllabus
97
8:32 am
Questions andPanel Discussion
Moderator: JonathanW. Kim,MD
Panel: Bita Esmaeli,MD, HakanDemirci,MD,MeredithBaker,MD,Maxwell Elia,MD
HenryBaylisCosmetic SurgeryAward Lecture
8:40 am
Introductionof theHenry I. BaylisAward Lecturer: Dr. GuyMassy
Roberta E. Gausas,MD
8:45 am
APersonal PerspectiveonTreating theEyelids andPeriorbitawith Injectable
HyaluronicAcidGels
Guy G.Massry,MD
The use of eyelid and periorbital fillers has evolved significantly over the last decade.A heightened awareness and understanding of
filler type and category, specific biochemical composition, flow characteristics, and potential for adverse outcomes has allowed better
clinical selection criteria based on desired result.Aswithmany “newer” or “novel” aesthetic interventions, an initial general euphoria
with applicability becomes appropriately replacedwith realistic expectations of outcome form both the physician (injector) and the
patient, asmeaningful experience is gained. Overall there has been a healthy advancement in thought from indiscriminant filling of
lines and folds of the face, to amore sophisticated realization of appropriate product selection and placement. Nowhere has this
been truer thanwith the use of fillers in the “high risk” periorbital area.This shift has been based on clinical experience, research,
and shared knowledge amongst core specialties involved in treatment of this delicate and often unforgiving area.With this inmind, I
generalize the important issues, and lessons learned,with the use of fillers to the eyelids and periorbita as follows
1. Awareness of the current economic trendswith regard to aesthetic revenue generation andmarket share of fillers
2. Knowledge of the relevant literature, anatomic nuances and product information available to improve treatment/results
3. A thorough understanding of HyaluronicAcidGels (HAG) – the only product I use to fill in this area.
4. Familiarizationwith appropriate injection technique
5. Identification of appropriate clinical indications/expected outcomes
6. Understanding the realm of potential complications – non-vascular/vascular
7. Being realisticwith patients.
The overview presentedwill bring a personal, yet contemporary perspective regardingHAG filling of the periorbital area.
9:20 am
Questions andDiscussion
9:25 am
Henry I. BaylisAwardPresentation
Roberta E. Gausas,MD
DetailedProgram
—Friday,October 17, 2014
